SOPH
Sophia Genetics SA
NASDAQ: SOPH · HEALTHCARE · HEALTH INFORMATION SERVICES
$5.28
+5.60% today
Updated 2026-04-29
Market cap
$358.34M
P/E ratio
—
P/S ratio
4.64x
EPS (TTM)
$-1.17
Dividend yield
—
52W range
$3 – $6
Volume
0.1M
Sophia Genetics SA (SOPH) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $25.36M | $28.40M | $40.45M | $47.56M | $62.37M | $65.17M | $77.27M |
| Revenue growth (YoY) | — | +12.0% | +42.4% | +17.6% | +31.1% | +4.5% | +18.6% |
| Cost of revenue | $7.53M | $10.71M | $15.23M | $16.31M | $19.46M | $21.24M | $29.46M |
| Gross profit | $17.83M | $17.69M | $25.22M | $31.25M | $42.91M | $43.94M | $47.81M |
| Gross margin | 70.3% | 62.3% | 62.4% | 65.7% | 68.8% | 67.4% | 61.9% |
| R&D | $15.02M | $18.59M | $26.58M | $35.37M | $36.97M | $34.37M | $33.57M |
| SG&A | $15.67M | $18.96M | $41.51M | $55.82M | $53.30M | $46.95M | $86.07M |
| Operating income | $-32.29M | $-37.39M | $-71.49M | $-87.82M | $-74.83M | $-66.57M | $-70.92M |
| Operating margin | -127.3% | -131.6% | -176.7% | -184.7% | -120.0% | -102.1% | -91.8% |
| EBITDA | $-30.74M | $-37.99M | $-69.24M | $-81.38M | $-69.57M | $-50.76M | $-61.40M |
| EBITDA margin | -121.2% | -133.8% | -171.2% | -171.1% | -111.5% | -77.9% | -79.5% |
| EBIT | $-32.65M | $-40.38M | $-72.85M | $-86.95M | $-77.91M | $-59.36M | $-70.92M |
| Interest expense | $976000.00 | $840000.00 | $658000.00 | $639000.00 | $588000.00 | $1.91M | $4.55M |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-33.79M | $-39.34M | $-73.67M | $-87.45M | $-78.98M | $-62.49M | $-79.00M |
| Net income growth (YoY) | — | -16.4% | -87.3% | -18.7% | +9.7% | +20.9% | -26.4% |
| Profit margin | -133.2% | -138.5% | -182.1% | -183.9% | -126.6% | -95.9% | -102.2% |